2. Search Result
Search Result
Results for "

Radioactivity

" in MedChemExpress (MCE) Product Catalog:

10

Inhibitors & Agonists

2

Peptides

1

Natural
Products

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-145461
    Hydroxy lenalidomide

    5-Hydroxy lenalidomide

    		 Others Others
    Hydroxy lenalidomide (5-Hydroxy lenalidomide) is a metabolite of lenalidomide that is present as a minor component in plasma and excreta, accounting for less than 5% of the total radioactivity, following oral administration of lenalidomide in healthy male subjects.
    Hydroxy lenalidomide
  • HY-E70260
    16-NBD-16:0 Coenzyme A triammonium

    		Acyltransferase Others
    16-NBD-16:0 Coenzyme A triammonium can be used as a substrate to measure the in vitro activity of other Acyltransferase .
    16-NBD-16:0 Coenzyme A triammonium
  • HY-14560
    Reboxetine

    		Others Neurological Disease
    Reboxetine is an orally active, potent and selective noradrenaline uptake blocker. Reboxetine can be used for antidepressant research .
    Reboxetine
  • HY-Y1091
    D-Lysine

    		Endogenous Metabolite Others
    D-Lysine is a useful raw material employed as an analog of lutenizing-hormone-releasing hormone and as a agent carrier in the form of polylysine. D-Lysine decreases renal uptake of radioactivity during scintigraphy and PRRT with low toxicity. D-Lysine not interferes with the natural amino acid metabolic balance .
    D-Lysine
  • HY-P10761
    DPI-4452

    		Radionuclide-Drug Conjugates (RDCs) Carbonic Anhydrase Cancer
    DPI-4452 is a CAIX-targeting cyclic peptide with a DOTA cage, and can be chelated with radionuclide for CAIX-expressing tumor PET-CT imaging and therapy. DPI-4452 specifically and selectively binds CAIX without interaction with an in vitro off-target receptor panel of 55 targets (IC50 for recombinant hCAIX: 130 nM). Radiolabeled DPI-4452 inhibits tumor growth in HT-29 and SK-RC-52 xenograft mouse models .
    DPI-4452
  • HY-163683
    EB-PSMA-617

    		Drug-Linker Conjugates for ADC Cancer
    EB-PSMA-617 is a modified form of PSMA-617 that has enhanced pharmacokinetic properties by conjugating it to Evans Blue (EB) to extend its circulation half-life to improve prostate tumor uptake and radiotherapy efficacy. In preclinical studies using PC3-PIP-loaded mice, EB-PSMA-617 demonstrated prolonged blood half-life, increased accumulation in PSMA-positive tumors, and successful tumor elimination with lower radioactivity .
    EB-PSMA-617
  • HY-129878
    N-Trifluoroacetyladriamycin

    AD-41

    		 Endogenous Metabolite Cancer
    N-Trifluoroacetyladriamycin (AD-41) is a chemotherapeutic compound with antitumor activity. N-Trifluoroacetyladriamycin exhibits the highest fluorescence and radioactivity levels in the small intestine and liver, indicating its significant accumulation in these tissues. N-Trifluoroacetyladriamycin also shows significant accumulation in the kidney, spleen, large intestine, lung, and heart. N-Trifluoroacetyladriamycin is a metabolite of Valrubicin, which is used to inhibit bladder cancer. The presence of N-Trifluoroacetyladriamycin and its derivatives may be related to the biotransformation of the compound and its antitumor mechanism .
    N-Trifluoroacetyladriamycin
  • HY-137263
    Propionylmaridomycin

    		Antibiotic Infection
    Propionylmaridomycin is a macrolide antibiotic with antibacterial activity. Propionylmaridomycin is rapidly absorbed from the gastrointestinal tract and rapidly distributed to tissues. Propionylmaridomycin radioactivity levels in the liver, kidneys, and lungs were significantly higher than in plasma, while distribution to the brain was less. Propionylmaridomycin is excreted primarily through the feces, and the high fecal recovery rate is due to unabsorbed compounds and biliary excretion of compounds and their metabolites. Propionylmaridomycin exhibits the highest antibacterial activity in the lungs. Propionylmaridomycin is completely converted to several metabolites in rats, of which 4''-depropionyl-9-propionylmaridomycin was identified as the major metabolite .
    Propionylmaridomycin
  • HY-121659
    DCFBC

    		PSMA Cancer
    DCFBC is a prostate-specific membrane antigen (PSMA) inhibitor that can be used for small animal positron emission tomography (PET) imaging. DCFBC labeled with F 18 ([18F]DCFBC) can images in severe combined immunodeficient mice. [18F]DCFBC uptake is higher in PIP tumors, but almost absent in FLU tumors. [18F]DCFBC uptake is also high in the kidney and bladder, but the radioactivity washout time is shorter than that in PIP tumors. Indicating that [18F]DCFBC can specifically localize to PSMA+ expressing tumors and is applicable to the study of prostate cancer .
    DCFBC
  • HY-W205529
    RO 16-6491 free base

    		Fluorescent Dye Neurological Disease
    RO 16-6491 Free base is a selective, reversible inhibitor of monoamine oxidase type B (MAO-B), exhibiting high affinity and specificity for binding sites in human frontal cortex mitochondria and platelet membranes. RO 16-6491 demonstrates a fast dissociation of bound radioactivity at 20 degrees C, indicating its dynamic binding properties. RO 16-6491 also acts as a substrate for MAO-B, suggesting that its oxidation may produce a stable intermediate responsible for its potent inhibitory effects. RO 16-6491 serves as an excellent radioligand probe for investigating the regional tissue distribution of MAO-B in various physiological and pathological states.
    RO 16-6491 free base

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: